- Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled AnalysisSong, Yuqin; Zhou, Keshu; Zou, Dehui; Li, Dengju; Hu, Jianda; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Jin, Jie; Lv, Fangfang; Feng, Ru; Gao, Sujun; Zhou, Daobin; Tam, Constantine S.; Simpson, David; Wang, Michael L.; Phillips, Tycel J.; Opat, Stephen; Fang, Cheng; Sun, Shaohui; Zhu, Jun64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 1
- Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upSong, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- PI3K δ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label TrialSu, Hang; Wang, Tingyu; Sun, Xiuhua; Qiu, Lihua; Cao, Junning; Li, Zhiming; Song, Yuqin; Zhang, Li; Li, Dengju; Wu, Huijing; Zhang, Wei; Li, Junmin; Zhou, Keshu; Zhou, Hui; Yang, Yu; Li, Zhifeng; Cen, Hong; Cai, Zhen; Zhang, Zhihui; Fu, Weijun; Jie, Jin; Li, Fei; Wu, Weixin; Gu, Xuekui; Zhu, Weiliang; Liu, Lihong; Li, Zengjun; Yi, Shuhua; Bao, Hanying; Xu, Zusheng; Qiu, Lugui65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study
16阅读
